AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03603574 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EWA through the needle
Description: In the EWA-N group, 5 mL of normal saline are injected through the epidural needle after the occurrence of loss-of-resistance (LOR). The needle is connected to the pressure transducer. A satisfactory endpoint is defined as the presence of waveforms synchronized with arterial pulsations. In the absence of pulsatile waveforms, the operator injects an additional 2.5 mL-bolus of normal saline through the epidural needle and reconnects the latter to the pressure transducer. If no waveforms are detected after the second injection, the operator removes the needle and reattempts the epidural block at a different intervertebral level. A maximum of 3 levels is permitted: if waveforms are still absent at the third level, the operator simply accepts LOR as the technical endpoint.
Study NCT03603574 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EWA through the catheter
Description: In the EWA-C group, the epidural catheter is advanced 5 cm beyond the needle tip after the occurrence of LOR. Subsequently, the operator injects 5 mL of normal saline through the catheter and the latter is connected to the pressure transducer via the sterile, rigid extension tubing. A satisfactory endpoint is defined as the presence of waveforms. In the absence of pulsatile waveforms, the operator injects an additional 2.5 mL-bolus of saline through the catheter and reconnects the latter to the pressure transducer. If no waveforms are detected after the second injection are still absent at the third level, the operator simply accepts this position for catheter placement (intent-to-treat analysis).
Study NCT04697108 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Shoulder reproduction teste assisted by laser pointer
Description: In the step (1) of Familiarization in which the SRTLP was applied through a single evaluator with the aim of knowledge and understanding of the test. After five minutes, step (2) test started. In this step, the test was applied twice, by different evaluators, with an interval of five minutes between applications (inter-rater reliability). Ten minutes after the end of the tests, step (3) retest (intra-rater reliability) was started, following the same procedures as in step 2. The order of the evaluators was randomized through a draw in Excel, the order of randomization of the steps (2) and (3) was the same in order not to influence intra-rater reliability
Study NCT03769389 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Birhi
Description: Birhi which contain the following:~43.6g of Freeze-dried date powder+ 150g of 0% fat yoghurt
Study NCT03769389 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Khassab
Description: 34.6g of freeze-dried date powder+ 150g of 0% fat yoghurt
Study NCT03769389 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: placebo
Description: 50g of pure glucose dissolved in 100ml of water
Study NCT03619902 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Imsidolimab
Description: Humanized monoclonal antibody
Study NCT00542217 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Imprime PGG
Study NCT01680146 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PRO+FAT
Study NCT01680146 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: PRO
Study NCT00803296 — intervention group
Intervention type: OTHER
Intervention: Oral glucose tolerance test (OGTT)
Study NCT00803296 — intervention group
Intervention type: OTHER
Intervention: Isoglycemic intravenous glucose infusion
Study NCT02726607 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV Infant Tracking System (HITSystem) 2.0
Description: The HITsystem 2.0 intervention will be designed to: (1) utilize electronic prompts to notify providers and program managers when actions are required, and (2) send text messages to women's mobile phones to (a) motivate adherence to medication, (b) remind women of antenatal (ANC) appointments and medication refills, (c) prompt preparation for a hospital delivery, and (d) support early infant testing. Given advancements in the approach and protocols for care, HITSystem 2.0 will continue to engage mothers and encourage postnatal medication adherence. The researchers will design HITSystem 2.0 to integrate seamlessly into the existing HITSystem to link PMTCT and early infant diagnosis (EID) services through one coordinated system-level intervention.
Study NCT02726607 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of PMTCT care
Description: Pregnant women enrolled in PMTCT services at the control site will receive the current standard of PMTCT care and will not be enrolled in the HITSystem 2.0.
Study NCT04469556 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folfirinox
Description: Chemotherapy
Study NCT04469556 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine/nab-paclitaxel
Description: Chemotherapy
Study NCT02080494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Study NCT01601873 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PROPATEN
Description: Heparin-bonded graft implantation for hemodialysis vascular access
Study NCT00510120 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Waitlist control
Description: Participants assigned to the waitlist control condition group will wait 10 weeks before beginning treatment one of the two treatment options.
Study NCT03920579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-386 formulation 1
Description: A single oral dose of 1 tablet under fasting conditions for each period
Study NCT02041065 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Waterjet induced dissection
Description: Waterjet induced dissection of the liver during resection.Waterjet dissection device mechanically separates hepatic tissue from bile ducts and vessels, the latter two to be separately ligated.
Study NCT02041065 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CUSA induced dissection
Description: Ultrasound based destruction of the liver
Study NCT02343783 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Allergic Skin Reaction (ASR) Testing and Skin Blister Induction
Description: Participants will not receive any intervention in this study. Healthy participants will be enrolled in order to allow for training on the overall skin blister induction and fluid aspiration process. The cell populations and inflammatory mediator responses in suction skin blister fluid after allergic skin reaction (ASR) in participants with atopic dermatitis (AD) or allergic asthma (AA) will be observed.
Study NCT00933257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LACTIC ACID(ND)
Description: Treatment duration 5 weeks
Study NCT05386940 — intervention group
Intervention type: OTHER
Intervention: PKN1 level
Description: different PKN1 level after on-pump cardiac surgery
Study NCT01162707 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CardioMEMS HF Pressure Measurement System
Description: Implant sensor into the left or right pulmonary artery. Measure pulmonary artery pressure
Study NCT02176785 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial Direct Current Stimulation (tDCS)
Description: tDCS will be delivered using a Chattanooga Ionto™ Iontophoresis System - Phoresor.
Study NCT02176785 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial Direct Current Stimulation (tDCS)
Description: tDCS will be delivered using a Chattanooga Ionto™ Iontophoresis System - Phoresor.
Study NCT02581397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transpulmin suppository
Description: 01 suppository in the morning and 01 at night, via rectal, for 03 or 07 days
Study NCT02581397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guaiacol suppository
Description: 01 suppository in the morning and 01 at night, via rectal, for 03 or 07 days
Study NCT02581397 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transpulmin syrup
Description: 7,5ml every 4 hours, orally, for 03 or 07 days
Study NCT03987321 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infrarenal vena cava filter placement
Description: Patients who are enrolled in this study are assigned to receive either Denali or Celect filter in the inferior vena cava. All other procedures are the same in both groups
Study NCT00564733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT03920592 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality of Bullying
Description: Immersive videos (360º) filmed by 12-14 year old pupils who, guided by professional actors, represented the subjective experience of bullying.~Eight different potential situations designed depending on the sex of the pupil were filmed:~Girls:~1. Classmates steal her personal diary~2. Classmates tear her clothing~3. Classmates insult her and steal her belongings~4. Classmates deliberately exclude her in class~Boys:~1. Classmates exclude him while playing with a ball~2. Classmates bother him in the dining room~3. Classmates insult and steal him in class~4. Classmates insult him and steal his belongings
Study NCT03671616 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IPV-Al SSI
Description: IPV-Al contains the reduced dose of IPV to be administered intramuscularly to the anterolateral of the right thigh. A single dose of the IPV-Al SSI will be given to infants age 15-18 months.
Study NCT03581409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin protect tablet
Study NCT03581409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: Prasugrel tablet
Study NCT03581409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel 75mg tablet
Study NCT03581409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol
Description: Cilostazol tablet
Study NCT00328692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rolofylline
Description: rolofylline 30 mg IV QD; 3 days
Study NCT00328692 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo (unspecified)
Description: rolofyline Pbo 30 mg IV QD; 3 days
Study NCT02977897 — intervention group
Intervention type: DRUG
Intervention: Octreotide Acetate
Description: Octreotide 100mcg SC q12h for 5 days
Study NCT05521659 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized oral care protocol
Description: Standardized oral care protocol (3 times a day at certain hours (06-14-22) with oral care set including chlorhexidine gluconate)
Study NCT02492659 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: femtosecond laser-assisted cataract surgery
Description: the femtosecond laser platform was used to generate capsulotomy with a diameter as described above in the control group, and lens fragmentation into 6 segments.
Study NCT02492659 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: conventional phacoemulsification
Description: continuous curvilinear capsulorhexis was performed with capsulorrhexis forceps. Following hydrodissection, phacoemulsification of the nucleus, aspiration of the residual cortex and capsular polishing were performed using a phacoemulsification machine
Study NCT04410237 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Med-Jet
Description: One half of each psoriasis plaque will be treated with a Med-Jet device and Triamcinolone acetonide (TAC) while the control half will be untreated.~One side of the body will be treated using a conventional syringe and the opposite side of the body will be treated using the Med-Jet needle-free injection device to verify efficacy, safety, and pain score
Study NCT04410237 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Syringe
Description: One half of each psoriasis plaque will be treated with a traditional syringe and Triamcinolone acetonide (TAC) while the control half will be untreated.~One side of the body will be treated using conventional syringe and the opposite side of the body will be treated using the Med-Jet needle-free injection device to verify efficacy, safety, and pain score
Study NCT03195335 — intervention group
Intervention type: OTHER
Intervention: Assessment via questionnaire
Description: All the children will be assessed via assessment questionnaires.
Study NCT00866879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus will initially be given at a dose of 2-4 mg orally (PO) daily. The dose will be modified to achieve 24 hours trough concentrations of 6-10 ng/ml by high-performance liquid chromatography (HPLC) assay. This medication will be given in an open label fashion. The first dose of sirolimus will be given at the time of randomization to those patients assigned to have tacrolimus switched to sirolimus.
Study NCT00866879 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Demographic Data, Medical History, and Donor Data
Description: Age at transplant, sex, race, cause of end-stage renal disease, medical history, donor age, cadaveric vs. living kidney transplant, histocompatibility/cross match data, viral serology, history of acute rejection and delayed graft function, use of induction therapy and immunosuppressants, use of Angiotensin Converting Enzyme Inhibitor (ACEI) and/or Angiotensin Receptor Blockers (ARB) level of renal allograft function-estimated GFR (e-GFR(12) using Modification of Diet in Renal Disease (MDRD) formula, proteinuria.
Study NCT00866879 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Demographic Data, Medical History, and Donor Data
Description: Age at transplant, sex, race, cause of end-stage renal disease, medical history, donor age, cadaveric vs. living kidney transplant, histocompatibility/cross match data, viral serology, history of acute rejection and delayed graft function, use of induction therapy and immunosuppressants, use of Angiotensin Converting Enzyme Inhibitor (ACEI) and/or Angiotensin Receptor Blockers (ARB) level of renal allograft function-estimated GFR (e-GFR(12) using Modification of Diet in Renal Disease (MDRD) formula, proteinuria.
Study NCT00866879 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood Draws for Control Group
Description: Subjects maintaining standard of care drug treatment of TAC and MMF will have monthly labs in addition to the baseline pre-randomization labs, at 6, 12, and 24 Months post-randomization. Peripheral blood leukocytes will be obtained.
Study NCT00866879 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Draws for Experimental Group
Description: This group will have monthly labs taken but will also have weekly labs during the period of conversion to monitor renal function and bone marrow function. In addition to the baseline pre-randomization labs, and labs collected at 6, 12, and 24 Months post-randomization, peripheral blood leukocytes will be obtained.
Study NCT00866879 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Donor Blood Draws
Description: Peripheral blood leukocytes from living donors obtained at the time of randomization. These donor leukocytes will be used as stimulator cells to study the functional activity of the recipient's lymphocytes function.
Study NCT00866879 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Donor Information
Description: Donor age, cadaveric vs. living donor, and histocompatibility and cross match to recipient
Study NCT00866879 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Kidney Biopsy
Description: Kidney biopsy at 24 Months to compare to the standard of care biopsy taken at 12 Months. This information will help evaluate renal allograft pathology and renal allograft tissue gene expression profiles of the two groups. Renal allograft biopsies will be stored in RNA later (preservative) to further extend knowledge on the effect of calcineurin-inhibitors (CI) free immunosuppression on gene expression profiles.
Study NCT00866879 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kidney Biopsy
Description: Kidney biopsy at 24 Months to compare to the standard of care biopsy taken at 12 Months. This information will help evaluate renal allograft pathology and renal allograft tissue gene expression profiles of the two groups. Renal allograft biopsies will be stored in RNA later (preservative) to further extend knowledge on the effect of calcineurin-inhibitors (CI) free immunosuppression on gene expression profiles.
Study NCT00160069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sagopilone (BAY86-5302, ZK 219477)
Description: 16 mg/m2, 3-hour infusion, every 3 weeks
Study NCT00160069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sagopilone (BAY86-5302, ZK 219477)
Description: 22 mg/m2, 30-min infusion, every 3 weeks
Study NCT00160069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sagopilone (BAY86-5302, ZK 219477)
Description: 22 mg/m2, 3-hour infusion, every 3 weeks
Study NCT01143766 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: gabapentin 900mg PO x 1 dose, 1 hour prior to the procedure
Study NCT01143766 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard sedation regimen
Description: Combination opiate and benzodiazepine will be administered to achieve moderate sedation. This is the standard of care.
Study NCT00338455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natrecor (nesiritide)+Standard Care+dobutamine or milrinone
Description: 3-hour 0.005 mcg/kg/min, may be titrated to 0.015 mcg/kg/min
Study NCT00338455 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo+Standard Care+dobutamine or milrinone
Description: 28-day continuous infusion, no bolus
Study NCT04190108 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fecal calprotectin assay
Description: FC levels were measured at baseline with Bühlmann fCAL Turbo, Switzerland® kit.
Study NCT01601873 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Graft
Description: non-heparin bonded conventional hemodialysis vascular access graft
Study NCT00138554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vildagliptin
Study NCT01172990 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate Invasive Management
Description: Patients allocated to the immediate invasive strategy will be taken to the catheter lab immediately (\< 90 minutes from randomisation) in accordance with local primary angioplasty policy. Angiogram +/- same sitting PCI will be performed according to local policy and guidelines
Study NCT01172990 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Management
Description: Patients allocated to the conventional management group will have medical stabilisation and will undergo angiogram +/- PCI between 24 to 48 hours from randomisation according to local policy and guidelines
Study NCT04330040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Tablet
Study NCT01018615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: silymarin
Description: capsules, 700 mg, twice daily, 12 days
Study NCT00564733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV
Study NCT01018615 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: green tea extract (EGCG)
Description: capsules, 196.5 mg, twice daily, 12 days
Study NCT04844567 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: COVVR_Synch
Description: Participants wear a respiration belt (Vernier, Go Direct) that continuously transmits thoracic circumference readings to a mobile phone (Samsung Galaxy S8) in real-time. The mobile device is placed in a headset (Zeiss VR ONEPLUS) and used to create a stereoscopic, immersive scene in Virtual Reality. The data from the respiration belt is used to map the on-going respiration pattern onto a virtual body in the scene in one of two feedback conditions.~COVVR_Synch provided synchronous feedback: participants receive real-time feedback of their respiration.
Study NCT04844567 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: COVVR_Asynch
Description: Participants wear a respiration belt (Vernier, Go Direct) that continuously transmits thoracic circumference readings to a mobile phone (Samsung Galaxy S8) in real-time. The mobile device is placed in a headset (Zeiss VR ONEPLUS) and used to create a stereoscopic, immersive scene in Virtual Reality. The data from the respiration belt is used to map the on-going respiration pattern onto a virtual body in the scene in one of two feedback conditions.~COVVR_Asynch provided asynchronous feedback: participants receive asynchronous, frequency modulated feedback of their respiration.
Study NCT02159001 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: electroconvulsive therapy
Description: 10-course, three times a week bilateral frontotemporal ECT
Study NCT02159001 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: electroconvulsive therapy
Description: 10-course, three times a week bilateral frontotemporal ECT
Study NCT03309241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06882961
Description: Single Ascending Doses of PF-06882961 from 3mg to TBD mg.
Study NCT03309241 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo Single Dose
Study NCT00564733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study NCT00564733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV
Study NCT00564733 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: Undergo FDG PET/CT
Study NCT00564733 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Undergo FDG PET/CT